Immune Responses to SARS-CoV-2 in Pediatric Populations

The paediatric immune response to SARS-CoV-2 differs markedly from that of adults, characterised by robust early innate activation, distinctive epithelial cell dynamics and efficient mucosal defences. Studies reveal heightened interferon signatures and specialised goblet cell responses in the paediatric airway that restrict viral replication. Adaptive immunity in children shows rapid yet transient antibody production, with durable spike-specific T and B cell memory in most cases. Humoral responses often feature cross-reactive neutralising antibodies against endemic coronaviruses, augmented by vaccination or hybrid immunity. Severe outcomes such as multisystem inflammatory syndrome in children remain rare, reflecting the balance between innate restraint and adaptive regulation. The longevity of protective immunity varies by variant exposure and vaccination status, informing booster strategies and vaccine regimens for younger age groups. Understanding these age-dependent mechanisms underpins public health measures, vaccine policy and therapeutic development to safeguard paediatric populations worldwide.

Research from Nature Portfolio

Age-specific epithelial investigations demonstrate that children’s nasal cultures harbour an interferon-activated goblet cell subtype that expresses high levels of antiviral genes and limits productive SARS-CoV-2 replication. Comparative studies show distinct differences in ACE2 and TMPRSS2 distribution across epithelial subtypes by age, correlating with reduced viral tropism in the paediatric airway. Longitudinal cohort research in school-aged children reveals persistent anti-spike IgG titres in over 90% of participants after 18 months, with higher neutralising capacity in those with hybrid immunity or vaccination against wild-type, Delta and Omicron variants. Seroconversion studies in daycare settings indicate that young children mount specific IgG responses at rates exceeding adults, influenced by viral load and timing of antibody assessment, suggesting strong early humoral imprinting that may protect against reinfection.

Immune Responses to SARS-CoV-2 in Pediatric Populations publication trend

The graph below shows the total number of articles in immune responses to sars-cov-2 in pediatric populations across all publications each year (not limited to Nature Index journals).

Technical terms

Interferon: A class of signalling proteins that activate antiviral defences in infected and neighbouring cells.

Goblet cell: An epithelial cell type in the respiratory mucosa responsible for mucus secretion and, in this context, producing antiviral factors.

Seroconversion: The transition from absence to presence of detectable specific antibodies in the blood following infection or vaccination.

Neutralising antibody: An antibody capable of binding to a virus and preventing its entry into host cells.

Multisystem inflammatory syndrome in children (MIS-C): A rare post-infectious hyperinflammatory condition affecting multiple organ systems following SARS-CoV-2 exposure.

References

1. Age-specific nasal epithelial responses to SARS-CoV-2 infection. Nature Microbiology (2024).
2. Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study. Nature Communications (2023).
3. SARS-CoV-2 seroconversion in children attending daycare versus adults in Germany between October 2020 and June 2021. Communications Medicine (2023).
4. Coronavirus disease 2019 (COVID-19) in children: Evolving epidemiology, immunology, symptoms, diagnostics, treatment, post–COVID-19 conditions, prevention strategies, and future directions. Journal of Allergy and Clinical Immunology (2024).
5. Immune responses to SARS-CoV-2 infection and vaccination in children. Seminars in Immunology (2023).
6. Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies. Frontiers in Immunology (2023).
7. Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults. Journal of Clinical Immunology (2023).
8. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology (2021).
9. Natural mucosal barriers and COVID-19 in children. JCI Insight (2021).